Skip to main content
Top
Published in: Virchows Archiv 6/2012

01-06-2012 | Original Article

TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma

Authors: C. Eloy, J. Santos, J. Cameselle-Teijeiro, P. Soares, M. Sobrinho-Simões

Published in: Virchows Archiv | Issue 6/2012

Login to get access

Abstract

Poorly circumscribed growth pattern, extra-thyroid extension and high intratumoural lymph vessel density are significantly associated to nodal metastatization in papillary thyroid carcinoma (PTC). It was also shown that transforming growth factor beta (TGF-beta)/Smad-dependent pathway activity is associated with local invasion, nodal metastatization and BRAF-mutated PTCs. We analysed the immunoexpression of TGF-beta, Smad2/Smad3, Smad4 and Smad7 in a series of 42 cases of classic PTC and 33 cases of follicular variant of PTC with known clinico-pathological and follow-up data, as well as BRAF and RAS status. The 75 PTCs were divided into poorly circumscribed (PCPTC) (n = 53) and well circumscribed (WCPTC) (n = 22) according to their borders. Nodal metastases were not detected in any WCPTC regardless of the presence of immunoexpression for TGF-beta, Smad2/Smad3, Smad4 and Smad7 and occurrence of BRAF mutation (in 20 % of WCPTCs). Increased cytoplasmatic expression of TGF-beta at the periphery of PCPTC was associated to morphological features of invasiveness, featuring the so-called epithelial-to-mesenchymal transition (EMT), and presence of nodal metastases, as well as to the occurrence of BRAF mutation which did not significantly alter, per se, the frequency of nodal metastases. The nuclear expression of Smad7 was more frequent in WCPTCs than in PCPTCs and was associated with unicentricity and absence of extra-thyroid extension, vascular invasion and nodal metastases. We conclude that nodal metastases are associated to poorly circumscribed, locally invasive PTCs that exhibit low levels of nuclear Smad7 and a peripheral EMT phenotype displaying TGF-beta overexpression, regardless of the occurrence of BRAF mutation.
Appendix
Available only for authorised users
Literature
1.
go back to reference DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC, Lyon DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC, Lyon
2.
go back to reference Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C (1985) Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794–804PubMedCrossRef Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C (1985) Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794–804PubMedCrossRef
3.
go back to reference Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79:564–573PubMedCrossRef Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79:564–573PubMedCrossRef
4.
go back to reference Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, Vieira de Castro I, Cardoso de Oliveira M, Fonseca E, Soares P, Sobrinho-Simões M (2006) PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213–220PubMedCrossRef Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, Vieira de Castro I, Cardoso de Oliveira M, Fonseca E, Soares P, Sobrinho-Simões M (2006) PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213–220PubMedCrossRef
5.
go back to reference Sobrinho-Simões M, Preto A, Rocha AS, Castro P, Máximo V, Fonseca E, Soares P (2005) Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 447:787–793PubMedCrossRef Sobrinho-Simões M, Preto A, Rocha AS, Castro P, Máximo V, Fonseca E, Soares P (2005) Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 447:787–793PubMedCrossRef
6.
go back to reference Castro P, Fonseca E, Magalhães J, Sobrinho-Simões M (2022) Follicular, papillary, and “hybrid” carcinomas of the thyroid. Endocr Pathol 13:313–320CrossRef Castro P, Fonseca E, Magalhães J, Sobrinho-Simões M (2022) Follicular, papillary, and “hybrid” carcinomas of the thyroid. Endocr Pathol 13:313–320CrossRef
7.
go back to reference Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle RM, Fagin JA, Ghossein RA (2010) Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histologic subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191–1200PubMedCrossRef Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle RM, Fagin JA, Ghossein RA (2010) Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histologic subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191–1200PubMedCrossRef
8.
go back to reference Eloy C, Santos J, Soares P, Sobrinho-Simões M (2011) Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. Virchows Archiv 459:595–605PubMedCrossRef Eloy C, Santos J, Soares P, Sobrinho-Simões M (2011) Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. Virchows Archiv 459:595–605PubMedCrossRef
9.
go back to reference Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 446:589–595PubMedCrossRef Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 446:589–595PubMedCrossRef
10.
go back to reference Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fiddler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216–222PubMedCrossRef Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fiddler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216–222PubMedCrossRef
11.
go back to reference Eloy C, Santos J, Soares P, Sobrinho-Simões M (2011) The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 459:265–276PubMedCrossRef Eloy C, Santos J, Soares P, Sobrinho-Simões M (2011) The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 459:265–276PubMedCrossRef
12.
go back to reference Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD (2007) Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A 104:2803–2808PubMedCrossRef Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD (2007) Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A 104:2803–2808PubMedCrossRef
13.
go back to reference Vasko VV, Saji M (2007) Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol 19:11–17PubMedCrossRef Vasko VV, Saji M (2007) Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol 19:11–17PubMedCrossRef
14.
go back to reference Liu Z, Kakudo K, Bai Y, Li Y, Ozaki T, Miyauchi A, Taniguchi E, Mori I (2011) Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition. J Clin Pathol 64:325–329PubMedCrossRef Liu Z, Kakudo K, Bai Y, Li Y, Ozaki T, Miyauchi A, Taniguchi E, Mori I (2011) Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition. J Clin Pathol 64:325–329PubMedCrossRef
15.
go back to reference Jensen K, Patel A, Hoperia V, Larin A, Bauer A, Vasko V (2010) Dynamic changes in e-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer. Exp Ther Med 1:457–462 Jensen K, Patel A, Hoperia V, Larin A, Bauer A, Vasko V (2010) Dynamic changes in e-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer. Exp Ther Med 1:457–462
16.
go back to reference Scarpino S, Cancellario d’Alena F, Di Napoli A, Pasquini A, Marzullo A, Ruco LP (2004) Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352–358PubMedCrossRef Scarpino S, Cancellario d’Alena F, Di Napoli A, Pasquini A, Marzullo A, Ruco LP (2004) Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352–358PubMedCrossRef
17.
go back to reference Miki H, Kitaichi M, Masuda E, Komaki K, Yamamoto Y, Monden Y (1999) ret/PTC expression may be associated with local invasion of thyroid papillary carcinoma. J Surg Oncol 71:76–82PubMedCrossRef Miki H, Kitaichi M, Masuda E, Komaki K, Yamamoto Y, Monden Y (1999) ret/PTC expression may be associated with local invasion of thyroid papillary carcinoma. J Surg Oncol 71:76–82PubMedCrossRef
18.
go back to reference Fonseca E, Nesland JM, Höie J, Sobrinho-Simões M (1997) Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Arch 430:239–245PubMedCrossRef Fonseca E, Nesland JM, Höie J, Sobrinho-Simões M (1997) Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Arch 430:239–245PubMedCrossRef
19.
go back to reference Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW (2002) Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 126:710–713PubMed Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW (2002) Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 126:710–713PubMed
20.
go back to reference Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ, Lee K-Y (2010) Unique patterns of tumour growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 23:1201–1208PubMedCrossRef Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ, Lee K-Y (2010) Unique patterns of tumour growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 23:1201–1208PubMedCrossRef
21.
go back to reference Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100PubMedCrossRef Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100PubMedCrossRef
22.
go back to reference Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella C, Sozzani S, Allavena P, Mantovani A, Ruco LP (2000) Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 156:831–837PubMedCrossRef Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella C, Sozzani S, Allavena P, Mantovani A, Ruco LP (2000) Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 156:831–837PubMedCrossRef
23.
go back to reference Fiumara A, Belfiore A, Russo G, Salomone E, Santonocito GM, Ippolito O, Vigneri R, Gangemi P (1997) In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. J Clin Endocrinol Metab 82:1615–1620PubMedCrossRef Fiumara A, Belfiore A, Russo G, Salomone E, Santonocito GM, Ippolito O, Vigneri R, Gangemi P (1997) In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. J Clin Endocrinol Metab 82:1615–1620PubMedCrossRef
24.
go back to reference Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15:1069–1074PubMedCrossRef Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15:1069–1074PubMedCrossRef
25.
go back to reference Hölting T, Zielke A, Siperstein AE, Clark O, Duh QY (1994) Transforming growth factor-beta1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines. J Clin Endocrinol Metab 79:806–813PubMedCrossRef Hölting T, Zielke A, Siperstein AE, Clark O, Duh QY (1994) Transforming growth factor-beta1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines. J Clin Endocrinol Metab 79:806–813PubMedCrossRef
26.
go back to reference Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P (2009) The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69:8317–8325PubMedCrossRef Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P (2009) The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69:8317–8325PubMedCrossRef
27.
go back to reference Kimura ET, Matsuo SE, Ricarte-Filho JC (2007) TGFbeta, activin and SMAD signaling in thyroid cancer. Arq Bras Endocrinol Metab 51:683–689CrossRef Kimura ET, Matsuo SE, Ricarte-Filho JC (2007) TGFbeta, activin and SMAD signaling in thyroid cancer. Arq Bras Endocrinol Metab 51:683–689CrossRef
28.
go back to reference Matsuo SE, Leoni SG, Colquhoun A, Kimura ET (2006) Transforming growth factor-β1 and activin A generate antiproliferative signaling in thyroid cancer cells. J Endocrinol 190:141–150PubMedCrossRef Matsuo SE, Leoni SG, Colquhoun A, Kimura ET (2006) Transforming growth factor-β1 and activin A generate antiproliferative signaling in thyroid cancer cells. J Endocrinol 190:141–150PubMedCrossRef
29.
go back to reference Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, SalzanoM NYE, Giordano TJ, Ghossein RA, Fagin JA (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30:3153–3162PubMedCrossRef Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, SalzanoM NYE, Giordano TJ, Ghossein RA, Fagin JA (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30:3153–3162PubMedCrossRef
31.
go back to reference ten Dijke P, Hill CS (2004) New insights into TGF-β-Smad signaling. Trends Biochem Sci 29:265–273PubMedCrossRef ten Dijke P, Hill CS (2004) New insights into TGF-β-Smad signaling. Trends Biochem Sci 29:265–273PubMedCrossRef
32.
go back to reference Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093PubMedCrossRef Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093PubMedCrossRef
33.
go back to reference Nicolussi A, D’Inzeo S, Santulli M, Colletta G, Coppa A (2003) TGF-beta control of rat thyroid follicular cells differentiation. Mol Cell Endocrinol 207:1–11PubMedCrossRef Nicolussi A, D’Inzeo S, Santulli M, Colletta G, Coppa A (2003) TGF-beta control of rat thyroid follicular cells differentiation. Mol Cell Endocrinol 207:1–11PubMedCrossRef
34.
go back to reference Morris JC 3rd, Ragnanathan G, Hay ID, Nelson RE, Jiang NS (1988) The effects of transforming growth factor-beta on growth and differentiation of the continuous rat thyroid follicular cell line, FRTL-5. Endocrinology 123:1385–1394PubMedCrossRef Morris JC 3rd, Ragnanathan G, Hay ID, Nelson RE, Jiang NS (1988) The effects of transforming growth factor-beta on growth and differentiation of the continuous rat thyroid follicular cell line, FRTL-5. Endocrinology 123:1385–1394PubMedCrossRef
35.
go back to reference Franzén A, Piek E, Westermark B, ten Dijke P, Heldin N-E (1999) Expression of transforming growth factor-beta1, activin A, and their receptors in thyroid follicle cells: negative regulation of thyrocytes growth and function. Endocrinology 140:4300–4310PubMedCrossRef Franzén A, Piek E, Westermark B, ten Dijke P, Heldin N-E (1999) Expression of transforming growth factor-beta1, activin A, and their receptors in thyroid follicle cells: negative regulation of thyrocytes growth and function. Endocrinology 140:4300–4310PubMedCrossRef
36.
go back to reference Bravo SB, Pampín S, Cameselle-Teijeiro J, Carneiro C, Domínguez F, Barreiro F, Alvarez CV (2003) TGF-β-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-κB activation. Oncogene 22:7819–7830PubMedCrossRef Bravo SB, Pampín S, Cameselle-Teijeiro J, Carneiro C, Domínguez F, Barreiro F, Alvarez CV (2003) TGF-β-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-κB activation. Oncogene 22:7819–7830PubMedCrossRef
37.
go back to reference Pisarev MA, Thomasz L, Juvenal GJ (2009) Role of transforming growth factor beta in the regulation of thyroid function and growth. Thyroid 19:881–892PubMedCrossRef Pisarev MA, Thomasz L, Juvenal GJ (2009) Role of transforming growth factor beta in the regulation of thyroid function and growth. Thyroid 19:881–892PubMedCrossRef
38.
go back to reference Kimura ET, Kopp P, Zbaeren J, Asmis LM, Ruchti C, Maciel RM, Studer H (1999) Expression of transforming growth factor beta1, beta2, and beta3 in multinodular goiters and differentiated thyroid carcinomas: a comparative study. Thyroid 9:119–125PubMedCrossRef Kimura ET, Kopp P, Zbaeren J, Asmis LM, Ruchti C, Maciel RM, Studer H (1999) Expression of transforming growth factor beta1, beta2, and beta3 in multinodular goiters and differentiated thyroid carcinomas: a comparative study. Thyroid 9:119–125PubMedCrossRef
39.
go back to reference Morosini PP, Taccaliti A, Montironi R, Scarpelli M, Diamanti L, Simonella G, Mancini V, Petrelli MD, Mantero F (1996) TGF-beta1 immunohistochemistry in goiter: comparison of patients with recurrence or no recurrence. Thyroid 6:417–422PubMedCrossRef Morosini PP, Taccaliti A, Montironi R, Scarpelli M, Diamanti L, Simonella G, Mancini V, Petrelli MD, Mantero F (1996) TGF-beta1 immunohistochemistry in goiter: comparison of patients with recurrence or no recurrence. Thyroid 6:417–422PubMedCrossRef
40.
go back to reference Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Fruglietti CU, Ferro MC, Kulcsar MA, Kimura ET (2010) Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arq Bras Endocrinol Metab 54:406–412CrossRef Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Fruglietti CU, Ferro MC, Kulcsar MA, Kimura ET (2010) Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arq Bras Endocrinol Metab 54:406–412CrossRef
41.
go back to reference Imamura Y, Jin L, Grande JP, Li C-Y, Zheng TR, Erickson LA, Lloyd RV (1998) Analysis of TGF-Β and TGF-Β-RII in thyroid neoplasms from the United States, Japan, and China. Endocr Pathol 9:209–216PubMedCrossRef Imamura Y, Jin L, Grande JP, Li C-Y, Zheng TR, Erickson LA, Lloyd RV (1998) Analysis of TGF-Β and TGF-Β-RII in thyroid neoplasms from the United States, Japan, and China. Endocr Pathol 9:209–216PubMedCrossRef
42.
go back to reference Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED, Wynford-Thomas D (1990) Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors 2:149–155PubMedCrossRef Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED, Wynford-Thomas D (1990) Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors 2:149–155PubMedCrossRef
43.
go back to reference Lloyd RV, Ferreiro JA, Jin L, Sebo TJ (1997) TGFB, TGFB receptors, Ki-67, and p27(Kip)l expression in papillary thyroid carcinomas. Endocr Pathol 8:293–300PubMedCrossRef Lloyd RV, Ferreiro JA, Jin L, Sebo TJ (1997) TGFB, TGFB receptors, Ki-67, and p27(Kip)l expression in papillary thyroid carcinomas. Endocr Pathol 8:293–300PubMedCrossRef
44.
go back to reference Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM, Kimura ET (2003) Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. J Endocrinol Invest 26:516–521PubMed Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM, Kimura ET (2003) Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. J Endocrinol Invest 26:516–521PubMed
45.
go back to reference D’Inzeo S, Nicollussi A, Ricci A, Mancini P, Porcellini A, Nardi F, Coppa A (2010) Role of reduced expression of SMAD4 in papillary thyroid carcinoma. J Mol Endocrinol 45:229–244PubMedCrossRef D’Inzeo S, Nicollussi A, Ricci A, Mancini P, Porcellini A, Nardi F, Coppa A (2010) Role of reduced expression of SMAD4 in papillary thyroid carcinoma. J Mol Endocrinol 45:229–244PubMedCrossRef
47.
go back to reference Nicolussi A, D’Inzeo S, Gismondi A, Coppa A (2006) Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-beta pathway. Clin Exp Metastasis 23:237–248PubMedCrossRef Nicolussi A, D’Inzeo S, Gismondi A, Coppa A (2006) Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-beta pathway. Clin Exp Metastasis 23:237–248PubMedCrossRef
48.
49.
go back to reference Asmis LM, Kaempf J, Von Gruenigen C, Kimura ET, Wagner HE, Studer H (1996) Acquired and naturally occurring resistance of thyroid follicular cells to the growth inhibitory action of transforming growth factor-b1 (TGF-β1). J Endocrinol 149:485–496PubMedCrossRef Asmis LM, Kaempf J, Von Gruenigen C, Kimura ET, Wagner HE, Studer H (1996) Acquired and naturally occurring resistance of thyroid follicular cells to the growth inhibitory action of transforming growth factor-b1 (TGF-β1). J Endocrinol 149:485–496PubMedCrossRef
50.
go back to reference Heldin NE, Bergström D, Hermansson A, Bergenstrahle A, Nakao A, Westermark B, ten Dijke P (1999) Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensivity in carcinoma cells. Mol Cell Endocrinol 153:79–90PubMedCrossRef Heldin NE, Bergström D, Hermansson A, Bergenstrahle A, Nakao A, Westermark B, ten Dijke P (1999) Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensivity in carcinoma cells. Mol Cell Endocrinol 153:79–90PubMedCrossRef
51.
go back to reference Coppa A, Mincione G, Mammarella S, Ranieri A, Colletta G (1995) Epithelial rat thyroid cell clones, escaping from transforming growth factor b negative growth control, are still inhibited by this factor in the ability to trap iodine. Cell Growth Differ 6:281–290PubMed Coppa A, Mincione G, Mammarella S, Ranieri A, Colletta G (1995) Epithelial rat thyroid cell clones, escaping from transforming growth factor b negative growth control, are still inhibited by this factor in the ability to trap iodine. Cell Growth Differ 6:281–290PubMed
52.
go back to reference Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA (2006) Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66:6521–6529PubMedCrossRef Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA (2006) Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66:6521–6529PubMedCrossRef
53.
go back to reference Lazzareschi D, Nardi F, Turco A, Ottini L, DÁmico C, Mariani-Constantini R, Gulino A, Coppa A (2005) A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene 24:5344–5354CrossRef Lazzareschi D, Nardi F, Turco A, Ottini L, DÁmico C, Mariani-Constantini R, Gulino A, Coppa A (2005) A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene 24:5344–5354CrossRef
54.
go back to reference Itóh S, Landström M, Hermansson A, Itoh F, Heldin CH, Heldin NE, ten Dijke P (1998) Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J Biol Chem 273:29195–29201PubMedCrossRef Itóh S, Landström M, Hermansson A, Itoh F, Heldin CH, Heldin NE, ten Dijke P (1998) Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J Biol Chem 273:29195–29201PubMedCrossRef
55.
go back to reference Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J (2010) Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol 34:868–872PubMedCrossRef Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J (2010) Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol 34:868–872PubMedCrossRef
56.
go back to reference Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef
Metadata
Title
TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma
Authors
C. Eloy
J. Santos
J. Cameselle-Teijeiro
P. Soares
M. Sobrinho-Simões
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 6/2012
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-012-1234-y

Other articles of this Issue 6/2012

Virchows Archiv 6/2012 Go to the issue